ViaCyte

We are excited to announce an agreement with W. L. Gore & Associates for novel membrane technology as well as a clinical update for our PEC-Encap product candidate. https://viacyte.com//viacyte-and-gore-enter-clinical-phas/ #sandiego #biotech #regenmed #t1d #diabetes #stemcells #celltherapy; JDRF

ICYMI - Lisa Hepner, director/producer of The Human Trial, shared her story last night on JDRF #Twitch TV, about what propelled her to film a documentary about pursuing a functional cure for #T1D and when the premiere might be. https://www.twitch.tv/videos/679858458 https://thehumantrial.com/

ViaCyte Appoints Brittany Bradrick as Chief Financial Officer https://viacyte.com//viacyte-appoints-brittany-bradrick-a/ #sandiego #biotech #regenmed #t1d #diabetes #stemcells #celltherapy

We are happy to announce today the continued support of our investors who have provided $27 million financing. We thank you all for your support as well, and hope you stay healthy and safe during this time. https://viacyte.com//viacyte-announces-27-million-financi/

We're headed to #SanFrancisco next week, and our CEO will be presenting Monday at #BiotechShowcase More info: https://viacyte.com//viacyte-to-present-at-biotech-showca/... #JPM2020 #JPM20 #BTS20 #regenmed #diabetes #T1D #regenerativemedicine

Happy Thanksgiving from ViaCyte! We are thankful for your support and for our team and collaborators who are dedicated to curing type 1 diabetes.

Coming up at the #ISSCR in Toronto: ViaCyte VP, Research and CSO Kevin D’Amour to speak at International Society for Stem Cell Research's From Stem Cell Biology to New Therapies on Nov. 6 http://bit.ly/2JMgVni #biotech #Toronto #health #T1D #type1diabetes #diabetes #regenerativemedicine #regenmed #clinicaltrials

We are happy to share an important #diabetes milestone. Preliminary data out today from ViaCyte’s PEC-Direct clinical trial show that implanted cells, when effectively engrafted, are capable of producing circulating C-peptide, a biomarker for insulin, in patients with type 1 #diabetes. Learn more: http://bit.ly/2odfjLZ Live webcast at 1:45pm: http://bit.ly/2odeeUe #biotech #SanDiego #health #T1D #type1diabetes #diabetes #regenerativemedicine #regenmed #clinicaltrials #stemcells #clinicaltrials

ViaCyte CEO and President Paul Laikind to present at 1:45 pm PT at the Cell & Gene Meeting on the Mesa: http://bit.ly/2mNkJfp #Mesa19 #biotech #SanDiego #health #T1D #type1diabetes #diabetes #regenerativemedicine #regenmed #clinicaltrials @alliancerm

Our CEO chatted with The Niche on our clinical progress and recent data presented at EASD with CRISPR Therapeutics. http://bit.ly/2mNhLrC #T1D #diabetes #regenerativemedicine #regenmed

News: CRISPR Therapeutics and ViaCyte present positive in vitro data towards a potential immune-evasive cell replacement therapy for #diabetes at a diabetes conference in Europe (EASD 2019). #EASD2019 #biotech #regenerativemedicine #health #T1D #regenmed #innovation https://viacyte.com//crispr-therapeutics-and-viacyte-prese

ViaCyte welcomes Paul J. Hastings and Ian F. Smith to the company’s Board of Directors. #biotech #regenerativemedicine #health #T1D #SanDiego #diabetes https://viacyte.com//viacyte-to-expand-board-of-directors-

We are pleased to welcome Sandra E. Poole to ViaCyte’s Board of Directors http://bit.ly/2Nk9O9W Sandra’s career has been focused on developing life-changing therapies. Her expertise in the area of product manufacturing is important as ViaCyte looks to scale-up production and potential regulatory approval of our cell therapy. #biotech #health #T1D #SanDiego #diabetes #regenerativemedicine #regenmed #business